<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176175</url>
  </required_header>
  <id_info>
    <org_study_id>0908/I/PRO</org_study_id>
    <nct_id>NCT01176175</nct_id>
  </id_info>
  <brief_title>Progesterone Microspheres Pharmacokinetic - Pharmacodynamic (PK-PD) Study</brief_title>
  <official_title>Randomized, Controlled, Open-label, Parallel, Clinical Trial to Assess Pharmacokinetics and Endometrial Effect of an Injectable Formulation of Progesterone Microspheres in Doses of 50 mg, 100 mg, 200 mg and 300 mg, in Postmenopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Productos Científicos S. A. de C. V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Productos Científicos S. A. de C. V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase: I pharmacokinetic - pharmacodynamic (PK-PD) study. Main objective: To establish the
      minimum effective dose of progesterone microspheres suspension, which administered by weekly
      intramuscular injection, will be able to induce transformation from a proliferative
      endometrium to a secretory endometrium.

      Study design: Randomized, controlled, open-label, parallel, dose-response clinical trial.

      Sites: 1 Subjects: 48 postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sites: 1 Phase: 1 Main objective:To establish the minimum effective dose of progesterone
      microspheres suspension, which administered by weekly intramuscular injection, will be able
      to induce transformation from a proliferative endometrium to a secretory endometrium.

      Secondary objectives:

        -  To determine and compare the steady-state pharmacokinetic profile of investigational
           products.

        -  To evaluate safety profile of investigational products in the study subjects.

        -  To evaluate local tolerability of investigational products in the study subjects.

      Study design:Randomized, controlled, open-label, parallel, dose-response clinical trial.

      Investigational products:

        -  Progesterone microspheres intramuscular injectable suspension 50 mg

        -  Progesterone microspheres intramuscular injectable suspension 100 mg

        -  Progesterone microspheres intramuscular injectable suspension 200 mg

        -  Progesterone microspheres intramuscular injectable suspension 300 mg Study subjects: 48
           healthy postmenopausal women, 45 - 60 years. Brief description: After written informed
           consent, 48 eligible women will receive pretreatment with oral estradiol valerate, then,
           14 days later, those with adequate endometrial thickness evaluated through ultrasound
           will be randomized to study treatments (one IM injection each 7 days, for a total of 7
           doses). 10 days after the first progesterone dose, an endometrial biopsy will be
           obtained. Blood samples will be obtained for pharmacokinetic study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial dating through histopathologic criteria.</measure>
    <time_frame>10 days</time_frame>
    <description>Endometrial dating according Noyes criteria as a measure of efficacy. At the moment of the biopsy, study subjects would have received 25 days of estradiol valerate pretreatment and 10 days of progesterone (investigational product); thus simulating the 25th day of a menstrual cycle. Efficacy will be measured as number of biopsies that have histological date according to cronological date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>0 -60 days.</time_frame>
    <description>Progesterone plasmatic concentrations and pharmacokinetic parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0 - 65 days</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability Pain Scores on a Visual Analog Scale</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone microspheres injectable suspension 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone microspheres injectable suspension 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone microspheres injectable suspension 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone microspheres injectable suspension 300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.</description>
    <arm_group_label>50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.</description>
    <arm_group_label>100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.</description>
    <arm_group_label>200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.</description>
    <arm_group_label>300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  45 to 60 years old

          -  Able to read and write

          -  Postmenopausal

          -  Body Mass Index equal or below 34.99 kg/m2

          -  Healthy

          -  Normal uterus

          -  Time availability

        Exclusion Criteria:

          -  Hypersensitivity to progesterone or related compounds

          -  Hypersensitivity to estrogens

          -  Hysterectomy

          -  History or present hormone-dependent tumor

          -  History or present uterine cervix dysplasia

          -  Abnormal and clinically-significant laboratory test results

          -  Family history of breast cancer

          -  History of thromboembolic disease

          -  Non-controlled hypertension

          -  History of stroke

          -  History of cardiac valve surgery

          -  Renal failure

          -  Hepatic failure

          -  Non-controlled diabetes

          -  Severe gastrointestinal disease

          -  History of serious neurologic disease

          -  Reduced mobility

          -  Anemia

          -  Previous or concomitant hormonal therapy

          -  Previous or concomitant therapy with inhibitors or inductors of cytochrome
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Bernardo, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación Mexicana para la Investigación Clínica, A. C. (AMIC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociación Mexicana para la Investigación Clínica, A. C. (AMIC)</name>
      <address>
        <city>Pachuca</city>
        <state>Hidalgo</state>
        <zip>42090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Productos Científicos S. A. de C. V.</investigator_affiliation>
    <investigator_full_name>Roberto Bernardo Escudero</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Progesterone</keyword>
  <keyword>Microspheres</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>Luteal phase support</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

